
At NC Holdings (“NCHD”), in a notable first for
AVI and a very rare occurrence at Japanese
AGMs in general, we had three shareholder
proposals successfully passed, with a further
three receiving majority shareholder support.
Two dividend-related resolutions were approved,
including an increase in the dividend pay-out
ratio to 70%, and the establishment of a stock-
compensation plan tied to achieving a three-year
total share price return of over 50% and an
average three-year ROIC of over 10%.
While we are pleased with this success, we are
disappointed that our shareholder proposals to
appoint two highly qualified outside directors
did not pass. In addition to largely ignoring
shareholder views for the past two years, the
board opposed six resolutions that achieved
majority shareholder support, engaged in
intimidation and baseless threats related to
purported concert party issues, targeted our
investment team members by name in both their
public and private rebuttals, and even attempted,
unsuccessfully, to claim that NCHD’s business
was of national interest to evade scrutiny at
the AGM. We will continue to engage with
management and seek solutions to improve
NCHD’s corporate value over the coming year.
Towards the end of the year, after almost five
years of private engagement, we released a
public statement expressing our opposition
to Digital Garage’s board of directors and
their misguided strategy. Critiquing the ill-
fated midterm plan released in May 2023, we
announced our intention to vote against all
directors at the upcoming AGM. We believe our
statement was well received and contributed to
raising awareness among other investors about
the necessary actions Digital Garage needs to
take to address its undervaluation.
Our private engagement accounts for most
of our work, and over the period, we sent
8 presentations and 17 letters to portfolio
companies. In our private engagements, we
cover more topics than shareholder proposals
allow, with a strong emphasis on operational
improvement, including strategies for margin
enhancement and growth. Our engagement
is tailored and specific to each company, with
our in-depth understanding highly appreciated
by management. We perceive ourselves
as providing a service akin to investment
consultants.
At the heart of our shareholder engagement is
a long-term approach, and while improvements
might not be reflected straight away, we believe
that through our suggestions we are helping
management create better businesses, ultimately
leading to higher returns for all shareholders.
In all cases, a track record demonstrating
our readiness to make our concerns public
significantly enhances our credibility in
interactions with boards and management.
While we can’t discuss all the details of our
private engagement, it was a busy period, and
there are several situations which we see coming
to a head in 2024, whether that be shareholder
proposals, mid-term plans or potential
privatisation events. We believe the potential for
alpha generation through engagement has never
been higher, and we are excited by the abundant
opportunities in the year ahead.
PORTFOLIO TRADING
Buying Activity
The largest purchase over the period was
Takuma, the waste treatment plant builder and
operator, which entered the portfolio in April.
Having observed Takuma from the sidelines
for several years, we witnessed the share price
boom +150% higher in an ESG-fuelled bubble
in 2021, only to decline by -46% to the price
at which we started buying. Given its open
shareholder register (32% foreign ownership), a
structural tailwind, and a shifting business model
to more recurring maintenance work (already
50%), we believe that Takuma’s lowly 6.7x EV/
EBIT valuation multiple is entirely unjustified.
Almost half of Takuma’s balance sheet assets
are held in cash and listed securities, accounting
for just over 60% of the market cap. We plan to
start engaging with management on solutions to
address the undervaluation in advance of next
year’s mid-term plan.
The second largest purchase was Eiken
Chemical, a diagnostics company specialising
in the manufacture of medical chemicals that
react with body samples to provide a diagnosis
for cancer, disease or infection. The market is
attractive, with high regulatory barriers to entry,
a razor/razor blade style business model and
stable growth driven by increased diagnostics
healthcare expenditure. Eiken Chemical has
produced a number of niche products, with the
most exciting being its Colon Cancer screening
test, called FIT (Faecal Immunochemical Test),
which accounts for around 40% of sales.
While generating low margins from the sale of
its analyser, Eiken Chemical earns high-margin
recurring income from the subsequent sales of
bottles and solutions, providing recurring sticky
income. Eiken Chemical’s global dominance is
driven by its testing accuracy and consistency,
proprietary technology in its buffer solution, and
the recognition of the OC-Sensor in over 100
journals, enhancing brand recognition and trust
with healthcare providers.
The appeal of the diagnostics business is not
lost on investors, with a set of peers, both
domestic and global, trading on an EV/EBIT of
26x vs Eiken’s 8x. We believe the disparity, in
part, is driven by a misunderstanding of its niche
business model, the roll-off from high margin
COVID-related reagents, and a bloated balance
sheet (32% of assets in net cash). We see almost
+100% upside to the current share price, and if
the company achieves its 2030 plan, possible
with the successful launch of a DNA based stool
test, over +200% upside.
Selling Activity
The largest sale was our long-standing position
Fujitec, where we generated a +111% ROI and
a +32% IRR over our almost five-year holding
period. This tremendous success was driven
by shareholder engagement, starting from the
release of our public presentation in May 2020,
and culminating with the recent overhaul of the
board of directors and ousting of the founding
family President. When we first invested in
Fujitec, it was trading on a 4.7x EV/EBIT multiple,
a significant discount compared to its peers
trading on 16.8x. Over the life of the investment,
that radically changed, and at the time of selling,
Fujitec was trading on a 23.3x EV/EBIT multiple,
a premium to peers’ 20.4x. We took the difficult
decision to sell the position based on valuation
grounds, believing that the exciting prospects
for value creation under the new board were
reflected in the higher valuation.
We sold our position in C Uyemura, which we
had been reducing for some time, generating
an 87% ROI and 21% IRR over the life of our
investment. We sold the last of our stake in
Teikoku Electric, following a strong appreciation
in the share price. Although it was only in the
portfolio for a year, we generated a 52% ROI,
amounting to a 92% IRR.
As has been the case for a few years, our
tolerance for companies with intransigent and
entrenched management who refuse to listen to
shareholder voices has diminished. This explains
our exits from Papyless, Pasona, Tokyo Radiator
and NS Solutions, as well as the reduction of
our stakes in two other small positions. AVI’s
approach is one of cooperative rather than
confrontational engagement, in contrast to some
other activist approaches. There are too many
well-run and undervalued companies in Japan,
with management teams who want to create
value for shareholders, to waste our time with
uncooperative companies that show little interest
in shareholder concerns.
AVI Japan Opportunity Trust plc / Annual Report 2023
IR G FS SI
13
SR